Work

Cost-effectiveness of universal HIV testing and treatment: where next?

Year: 2021

Type: article

Abstract: The HPTN 071 (PopART) trial and others have shown that a combination HIV prevention package, including universal testing and treatment (UTT), can reduce the population-level incidence of HIV compared with standard care.1,2 However, evidence on the cost and cost-effectiveness of this strategy has been limited. In The Lancet Global Health, Ranjeeta Thomas and colleagues3 report on a cost-effectiveness analysis model, projecting that combination HIV prevention including UTT (ie, PopART) is cost-effective at thresholds greater than US$800 per disability-adjusted life year (DALY) averted in individuals older than 14 years.

Source: The Lancet Global Health

DOI: 10.1016/s2214-109x(21)00089-9

Authors: Jean B Nachega, Ethan D Borre, David W Dowdy, Pascalina Chanda-Kapata, Susan Cleary, Elvin H Geng